Biotech & Life SciencesEducationMobility & TransportationHealthcareTravel & HospitalityData & AnalyticsAI
Boyu Capital primarily focuses on making significant private equity investments in established, large-scale Chinese companies across sectors like technology, healthcare, and consumer. Their strategy involves active engagement and strategic guidance to drive growth and operational improvements within their portfolio companies.
42% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $472.6M (across 12 rounds with reported amounts).
Portfolio
12
Fund Size
$40B
Top Stage
Growth
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
12 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| ZZeekr Intelligent Technology Co. | Series A | $500M | Aug 2021 |
| SShanghai MediTrust Health Technology Co., Ltd. | Series C | $308M | Aug 2021 |
 Yuanfudao | Series G | $2.2B | Oct 2020 |
 Antengene Corporation | Series C | $97M | Jul 2020 |
 Klook | Growth | $200M | Aug 2018 |
 Trax | Growth | $125M | Jul 2018 |
| BBrii BioSciences | Growth | $260M | May 2018 |
 FogPharma | Series B | $66M | May 2018 |
| CCStone Pharmaceuticals | Series B | $260M | May 2018 |
 LifeMine Therapeutics | Series A | $55M | Sep 2017 |
 Megvii | Growth | $600M | — |
| Yuanfudao | Unknown | $1B | — |
Top Co-Investors
ARCH Venture Partners3 shared
Blue Pool Capital3 shared
Hillhouse Capital3 shared
GIC3 shared
Tencent Investment2 shared
IDG Capital2 shared
DST Global2 shared
CITICPE2 shared
Temasek Holdings2 shared
TBP2 shared
Ocean Link2 shared
Greenwoods2 shared
Sequoia China2 shared
WuXi Healthcare Ventures2 shared
Alliance Ventures1 shared
Marathon1 shared
Lilly Asia Ventures1 shared
Bank of China Group Investment1 shared
Sinovation1 shared
Sequoia Capital1 shared
Last updated: 15 April 2026